Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360335 | 0.90 | POLB (0.42) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20503314 | 0.88 | LMNA (0.44) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL973113 | 0.87 | LMNA (0.50) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4787730 | 0.86 | POLB (0.51) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7699075 | 0.86 | LMNA (0.49) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6713457 | 0.85 | LMNA (0.44) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5900613 | 0.84 | LMNA (0.48) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL1299 | 0.84 | SMN1; SMN2 (0.45) | POLBSMN1; SMN2RAB9AMAPTFAAH | |
| SCHEMBL7703155 | 0.83 | LMNA (0.47) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL14109576 | 0.81 | LMNA (0.45) | POLBLMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-114369064-A | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| CN-103044331-B | Prepare the new method of the formamide of 3 n-propyl pyrazoles of silaenafil intermediate 4 amino, 1 methyl 5 | 常州市亚邦医药研究所有限公司 | 2017-09-15 | — | — | CN | claimed |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| CN-103044331-A | Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide | CHANGZHOU YABANG PHARMACEUTICAL INST CO LTD | 2013-04-17 | — | — | CN | claimed |
| JP-10204063-A | — | — | None | — | — | JP | disclosed |
| WO-2025049827-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING PYRAZOLE DERIVATIVES | OSMO LABS, PBC (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | POLB 2408/4885LMNA 2257/4885SMN1; SMN2 1902/4885 |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | POLB 2408/4885LMNA 2257/4885SMN1; SMN2 1902/4885 |
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | POLB 2024/4885LMNA 962/4885SMN1; SMN2 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.